Fortress Biotech Inc. has released its unaudited pro forma condensed statements of operations for the year ended December 31, 2024. The company's pro forma revenue remained consistent, with product revenue totaling $55.1 million and collaboration revenue at $1.5 million. However, revenue from related parties was eliminated, resulting in no contribution from this segment. The company reported a significant improvement in net income. The pro forma net gain attributable to Fortress was $17.1 million, compared to a net loss of $10.6 million as reported. This positive shift is largely due to a $26.6 million pre-tax gain from the sale of Checkpoint, which was a notable adjustment in the financial results. Operating expenses saw a reduction, with total operating expenses decreasing to $24.3 million from $35.5 million as reported, following adjustments including the elimination of costs directly attributable to Checkpoint. The net loss attributable to common stockholders improved from a reported loss of $12.7 million to a pro forma net gain of $15 million. This was reflected in the net loss per common share attributable to common stockholders, which improved from a reported loss of $0.48 to a pro forma gain of $0.57 per share. The company did not provide specific outlook or guidance for the upcoming periods in the report.